Fig. 4: Course of left ventricular ejection fraction (measured by echocardiography) in patients suffering from AML. | Leukemia

Fig. 4: Course of left ventricular ejection fraction (measured by echocardiography) in patients suffering from AML.

From: IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis

Fig. 4

a Ejection fraction in the weighted study cohort comparing IDH2 versus wildtype IDH1/2 and b in the unweighted study cohort. c Left ventricular ejection fraction in the weighted study cohort comparing IDH1/2 mutated versus wildtype IDH1/2 d and in the unweighted study cohort. e Ejection fraction in the unweighted study cohort comparing IDH1 mutated versus wildtype IDH1/2. *p < 0.05, **p < 0.01, ***p < 0.001 comparing wildtype IDH1/2 with mutated IDH2 at the corresponding timepoints (tx). #p < 0.05, ##p < 0.01, ###p < 0.001 comparing the corresponding timepoint within the same group with timepoint t0. t0 denotes the timepoint prior to AML therapy and t1–3 show the ejection fraction at different timepoints after AML therapy. Mut mutated, WT wildtype. All data shown are mean, error bars represent ±SD.

Back to article page